Nutrient broth comprising listeria phage for use as targeting tools to prevent grampositive bacterial growth in food products
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberIntralytixIntralytixIntralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Publication Number
US-7507571-B2
Publication Date
2009-03-24
Expiration Date
Abstract
The present invention is directed to isolated Listeria monocytogenes bacteriophage, and methods of using Listeria monocytogenes bacteriophage, or polynucleotides and polypeptides derived therefrom, to control the growth or contamination of food products by Listeria monocytogenes. The present invention also contemplates the use of Listeria monocytogenes bacteriophage, and polynucleotides and polypeptides derived therefrom, for the treatment of host infections or environmental contamination by Listeria monocytogenes.
Core Innovation
The invention provides isolated bacteriophages of bacteriophage strains selected from the group consisting of List-1, List-2, List-3, List-4, List-36, and List-38, deposited under ATCC Accession Nos. PTA-5372, PTA-5373, PTA-5374, PTA-5375, PTA-5376, and PTA-5377, respectively, and variants thereof. The variants retain the phenotypic characteristics of the deposited phage and the bacteriophages are characterized by lytic activity against Listeria monocytogenes strains.
The document further describes phage-derived polynucleotides and polypeptides for detection purposes, including reporter phage systems and hybridization/PCR-related components, as well as epidemiological typing. The described bacteriophages include variants/derivatives and are screened for lytic specificity against Listeria monocytogenes strains, including testing of susceptibility across a collection of strains and reporting proportions susceptible to a six-phage cocktail.
The invention is directed to controlling Listeria monocytogenes contamination and colonization, including in food products and food-processing equipment, and to environmental decontamination. The document also describes treating mammalian (human/animal) infections caused by Listeria monocytogenes.
Claims Coverage
Two independent claims are identified. Each independent claim requires an isolated bacteriophage from specified deposited List strains, retention of phenotypic characteristics in variants, and lytic activity against Listeria monocytogenes strains.
Isolated bacteriophage retaining phenotypic characteristics and lytic activity against Listeria monocytogenes strains
An isolated bacteriophage of a bacteriophage strain selected from List-1, List-2, List-3, List-4, List-36, and List-38 deposited under ATCC Accession Nos. PTA-5372, PTA-5373, PTA-5374, PTA-5375, PTA-5376, and PTA-5377, respectively, and variants thereof, wherein the variants retain the phenotypic characteristics of the deposited phage, and wherein the bacteriophage, and variants thereof, have lytic activity against Listeria monocytogenes strains.
Isolated bacteriophage retaining phenotypic characteristics and lytic activity against Listeria monocytogenes strains
An isolated bacteriophage of a bacteriophage strain selected from List-1, List-2, List-4, List-36, and List-38 deposited under ATCC Accession Nos. PTA-5372, PTA-5373, PTA-5375, PTA-5376, and PTA-5377, respectively, and variants thereof, wherein the variants retain the phenotypic characteristics of the deposited phage, and wherein the bacteriophage, and variants thereof, have lytic activity against Listeria monocytogenes strains.
Across both independent claims, the inventive scope centers on isolated bacteriophages, including variants retaining deposited phenotypic characteristics, selected from specified ATCC-deposited List strains, with the defining functional requirement of lytic activity against Listeria monocytogenes strains.
Stated Advantages
Control of Listeria monocytogenes contamination and colonization in food products and food-processing equipment.
Environmental decontamination of Listeria monocytogenes.
Detection of Listeria monocytogenes using phage-derived polynucleotides and polypeptides, including hybridization/PCR and reporter phage systems.
Epidemiological typing.
Treating mammalian (human/animal) infections caused by Listeria monocytogenes.
Documented Applications
Controlling Listeria monocytogenes contamination and colonization in food products and food-processing equipment.
Environmental decontamination.
Treating mammalian (human/animal) infections caused by Listeria monocytogenes.
Detection of Listeria monocytogenes using phage-derived polynucleotides and polypeptides (hybridization/PCR and reporter phage systems).
Epidemiological typing.
Interested in licensing this patent?